Good AI Capital

Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Stellic (previously known as Metis) was founded by Carnegie Mellon undergraduates after getting frustrated by the clunky, complicated tools they were given to plan their academic journey. Under the mentorship of university advisors who were equally frustrated with the existing degree planning process, the team pursued their goal of building a planner with intelligence and interation. The project received appreciation from the campus community and won Research Awards – convincing the team to build a company with a purpose to provide student-built tools to universities worldwide.

Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.

Playco is an instant-play gaming company that develops games that billions of people can play together. The company works closely with a vast network of partners from global tech and social media giants to new startups developing innovative technologies.

Keatext will help you cultivate meaningful relationships with your customers by providing you with instant clarity on what they care about most, and by increasing your ability to respond rapidly to their needs by synthesizing large volumes of unstructured feedback data from multiple channels (such as open-survey questions, online reviews, chat logs and social media posts) to produce actionable insights delivered on one comprehensive custom dashboard.

Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.

Uplift is an enterprise buy now, oay later solution serving over 100 of the world's top travel brands. Through personalized, flexible payment options, Uplift helps consumers take control of their budget and experience a world of travel. With a complete range of payment options, Uplift unlocks higher conversions and lifetime customer value for merchant partners.